Monopar Therapeutics GAAP EPS of $0.38
Source: SeekingAlpha
2025-05-13 14:43:12 ET
More on Monopar Therapeutics
- Monopar Therapeutics: Strong Data, But There Are Risks
- Monopar a new overweight at Piper Sandler on rare disease asset
- Seeking Alpha’s Quant Rating on Monopar Therapeutics
- Historical earnings data for Monopar Therapeutics
- Financial information for Monopar Therapeutics
Read the full article on Seeking Alpha
For further details see:
Monopar Therapeutics GAAP EPS of $0.38
Monopar Therapeutics Inc.
NASDAQ: MNPR
MNPR Trading
-0.45% G/L:
$57.02 Last:
56,304 Volume:
$56.34 Open:
MNPR Latest News
March 02, 2026 08:00:00 am
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
November 13, 2025 08:00:00 am
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments
MNPR Stock Data
$384,114,928
4,169,932
0.03%
12
N/A
Biotechnology & Life Sciences
Healthcare
US
Wilmette
